Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights DOI Creative Commons

Ping‐Pin Zheng,

Jin Li, Johan M. Kros

и другие.

Medicinal Research Reviews, Год журнала: 2017, Номер 38(1), С. 325 - 376

Опубликована: Сен. 1, 2017

Abstract To date, five cancer treatment modalities have been defined. The three traditional of are surgery, radiotherapy, and conventional chemotherapy, the two modern include molecularly targeted therapy (the fourth modality) immunotherapy fifth modality). cardiotoxicity associated with chemotherapy radiotherapy is well known. Similar adverse cardiac events resurging modality. Aside from newer agents, even most newly developed, immune‐based therapeutic anticancer modality), e.g., immune checkpoint inhibitors chimeric antigen receptor (CAR) T‐cell therapy, unfortunately led to potentially lethal in patients. Cardiac complications represent unresolved life‐threatening conditions survivors, while effective clinical management remains quite challenging. As a consequence, morbidity mortality related now threaten offset some favorable benefits treatments cancer‐related survival, regardless oncologic prognosis. This review focuses on identifying critical research‐practice gaps, addressing real‐world challenges pinpointing real‐time insights general terms under context induced by treatment. information ranges basic science field cardio‐oncology crosses interface between oncology onco‐pharmacology. complexity ongoing problem addressed at different levels. A better understanding these gaps may advance research initiatives development mechanism‐based diagnoses for cardiotoxicity.

Язык: Английский

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms DOI

Sariah Liu,

Razelle Kurzrock

Cancer Treatment Reviews, Год журнала: 2014, Номер 40(7), С. 883 - 891

Опубликована: Май 17, 2014

Язык: Английский

Процитировано

150
Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome DOI
Heather Yvonne Small, Augusto C. Montezano, Francisco J. Rios

и другие.

Canadian Journal of Cardiology, Год журнала: 2014, Номер 30(5), С. 534 - 543

Опубликована: Фев. 25, 2014

Язык: Английский

Процитировано

123
Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit DOI
Rashmi R. Shah,

Joel Morganroth

Drug Safety, Год журнала: 2015, Номер 38(8), С. 693 - 710

Опубликована: Май 25, 2015

Язык: Английский

Процитировано

108
Targeting STAT3 in cancer and autoimmune diseases DOI
Tohid Gharibi, Zohreh Babaloo, Arezoo Hosseini

и другие.

European Journal of Pharmacology, Год журнала: 2020, Номер 878, С. 173107 - 173107

Опубликована: Апрель 9, 2020

Язык: Английский

Процитировано

87
Clinically relevant drug interactions with multikinase inhibitors: a review DOI Creative Commons
Koen G. A. M. Hussaarts,

G. Veerman,

Frank G. A. Jansman

и другие.

Therapeutic Advances in Medical Oncology, Год журнала: 2019, Номер 11

Опубликована: Янв. 1, 2019

Multikinase inhibitors (MKIs), including the tyrosine kinase (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice. Although oral route of administration offers improved flexibility and convenience for patient, challenges arise use MKIs. As MKIs are prescribed extensively, patients at increased risk (severe) drug–drug interactions (DDIs). a result these DDIs, plasma pharmacokinetics may vary significantly, thereby leading to high interpatient variability subsequent toxicity or diminished therapeutic outcome. Most clinically relevant DDIs with concern altered absorption metabolism. The be decreased by concomitant gastric acid-suppressive agents (e.g. proton pump inhibitors) as many show pH-dependent solubility. In addition, concerning drug (uptake efflux) transporters significant clinical relevance during MKI therapy. Furthermore, since substrates cytochrome P450 isoenzymes (CYPs), induction inhibition strong CYP inducers lead alterations exposure. conclusion, major therapy need monitored closely Based on current knowledge available literature, practical recommendations management practice presented this review.

Язык: Английский

Процитировано

79
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology DOI
Rashmi R. Shah,

Devron R. Shah

Drug Safety, Год журнала: 2019, Номер 42(2), С. 181 - 198

Опубликована: Янв. 16, 2019

Язык: Английский

Процитировано

76
Cardiotoxic effects of angiogenesis inhibitors DOI Creative Commons
Stephen J.H. Dobbin, Mark C. Petrie, Rachel C. Myles

и другие.

Clinical Science, Год журнала: 2021, Номер 135(1), С. 71 - 100

Опубликована: Янв. 1, 2021

The development of new therapies for cancer has led to dramatic improvements in survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising treatment a wide range malignancies. However, these drugs are associated with cardiovascular toxicities which can impact optimal the short-term and may lead increased morbidity mortality longer term. Vascular endothelial growth factor (VEGFIs) hypertension, left ventricular systolic dysfunction (LVSD) heart failure as well arterial venous thromboembolism, QTc interval prolongation arrhythmia. mechanisms behind VEGFI-associated LVSD likely involve combination number myocardial insults. These include direct effects, secondary toxicity via coronary or peripheral vascular damage. Cardiac result from 'on-target' effects VEGF inhibition 'off-target' resulting other tyrosine kinases. Similar be involved right (RV) dysfunction. Some VEGFIs an risk atrial Further pre-clinical clinical studies trials needed better understand VEGFI on system. Once elucidated, investigated surveillance strategies identifying complications developed.

Язык: Английский

Процитировано

66
Oncologic emergencies and urgencies: A comprehensive review DOI Open Access
Bonnie E. Gould Rothberg, Tammie E. Quest, Sai‐Ching J. Yeung

и другие.

CA A Cancer Journal for Clinicians, Год журнала: 2022, Номер 72(6), С. 570 - 593

Опубликована: Июнь 2, 2022

Abstract Patients with advanced cancer generate 4 million visits annually to emergency departments (EDs) and other dedicated, high‐acuity oncology urgent care centers. Because of both the increasing complexity systemic treatments overall higher rates active therapy in geriatric population, many patients experiencing acute decompensations are frail acutely ill. This article comprehensively reviews spectrum oncologic emergencies urgencies typically encountered settings. Presentation, underlying etiology, up‐to‐date clinical pathways discussed. Criteria for either a safe discharge home or transition inpatient hospitalist team emphasized. review extends beyond familiar conditions such as febrile neutropenia, hypercalcemia, tumor lysis syndrome, malignant spinal cord compression, mechanical bowel obstruction, breakthrough pain crises include broader topics encompassing syndrome inappropriate antidiuretic hormone secretion, venous thromboembolism effusions, well chemotherapy‐induced mucositis, cardiomyopathy, nausea, vomiting, diarrhea. Emergent complications associated targeted therapeutics, including small molecules, naked drug‐conjugated monoclonal antibodies, immune checkpoint inhibitors chimeric antigen receptor T‐cells, summarized. Finally, strategies facilitating same‐day direct admission hospice from ED not only can serve point‐of‐care reference physician but also assist outpatient oncologists hospitalists coordinating around visit.

Язык: Английский

Процитировано

64
The state of the art in secondary pharmacology and its impact on the safety of new medicines DOI
Richard Brennan, Stephen Jenkinson, Andrew J. Brown

и другие.

Nature Reviews Drug Discovery, Год журнала: 2024, Номер 23(7), С. 525 - 545

Опубликована: Май 21, 2024

Язык: Английский

Процитировано

12
Dasatinib‐Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukaemia: A Case Report and Literature Review DOI Creative Commons

Sathish Krishnan,

Sashi Adigopula

Respirology Case Reports, Год журнала: 2025, Номер 13(3)

Опубликована: Март 1, 2025

ABSTRACT Dasatinib, a second‐generation tyrosine kinase inhibitor used for treating chronic myeloid leukaemia (CML), is associated with rare but significant adverse effects, including pulmonary arterial hypertension. This condition thought to result from endothelial dysfunction and vascular remodelling linked Src inhibition. Symptoms such as progressive dyspnoea fatigue may appear months or years after starting therapy, emphasising the need long‐term vigilance. We present case of 55‐year‐old female CML who developed severe pre‐capillary hypertension prolonged dasatinib use. Diagnosis was confirmed via echocardiography right heart catheterisation, other causes excluded. Following discontinuation, initiation targeted PAH replacement imatinib, patient showed clinical haemodynamic improvement.

Язык: Английский

Процитировано

1